STOCK TITAN

Aurora Cannabis Inc. Common Shares - ACB STOCK NEWS

Welcome to our dedicated page for Aurora Cannabis Common Shares news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis Common Shares stock.

Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) is a prominent Canadian company headquartered in Edmonton, Alberta, dedicated to the cultivation, production, and sale of high-quality cannabis for both medical and recreational use. The company's state-of-the-art facilities in Alberta embody advanced cultivation techniques that ensure the highest standards of quality, reliability, and safety in their products. Aurora's comprehensive portfolio includes renowned brands like Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, catering to a wide range of consumer preferences.

Aurora's operations extend beyond Canada, with significant international presence through medical cannabis exporting agreements. A notable subsidiary, Australis Capital Inc., plays a crucial role in participating in the U.S. cannabis market. The company's commitment to quality is further highlighted by its EU-GMP and TGA-GMP certified production facilities, ensuring compliance with rigorous international standards.

In recent developments, Aurora has launched three new cannabis-infused beverages targeted initially at veteran patients. These products, featuring innovative SōRSE® emulsion technology, offer an alternative form of cannabis consumption without the strong cannabis aroma or taste. Available in flavors like Neon Rush, Strawberry Pineapple Tropical Fizz, and Pineapple Coconut Fizz, these beverages are designed to enhance patient wellbeing with a refreshing and potent experience.

Financially, Aurora has achieved significant milestones, including the repayment of nearly $465 million in convertible debt and forecasting positive free cash flow for calendar 2024. The company has also strengthened its global footprint by acquiring MedReleaf Australia's majority equity, further solidifying its position in the Australian market. Aurora’s commitment to financial discipline and strategic expansions underscores its potential for sustainable growth.

Aurora's dedication to innovation and patient care is exemplified through its continuous development of new products and partnerships. Their recent launches include resin cartridges and pastilles in Australia, expanding their product range and enhancing patient access to premium medical cannabis. Additionally, the company's strategic moves in Europe, particularly in Germany, position it as a leader in the evolving cannabis landscape.

With a robust pipeline of products and strategic market expansions, Aurora Cannabis Inc. continues to pave the way for significant advancements in the global cannabis industry, committed to improving lives through high-quality, innovative cannabis products.

Rhea-AI Summary

High Tide Inc. has announced a definitive agreement to acquire 80% of NuLeaf Naturals for US$31.24 Million, enhancing its CBD market presence. This acquisition will boost High Tide's U.S. revenue run rate by approximately C$70 Million, leading to a pro forma annual revenue run rate of C$80 Million outside Canada. NuLeaf's revenue for the past year was US$19.4 Million, with a gross margin of 71%. The acquisition aims to leverage manufacturing synergies and expand product offerings across various platforms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
-
Rhea-AI Summary

Aurora Cannabis has unveiled a new genetics licensing business unit called Occo, aimed at advancing cannabis cultivation and commercialization. Led by Casey Whelan, VP of Genetics Business Development, Occo will utilize Aurora's state-of-the-art facility in Comox, British Columbia. Occo boasts the largest catalogue of high-quality cannabis genetics in Canada, with over 30 exclusive cultivars ready for licensing. The initiative is expected to enhance scientific understanding and product quality in the cannabis market, benefiting both growers and consumers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
none
-
Rhea-AI Summary

Aurora Cannabis announced the results of its Annual General Meeting held on November 12, 2021, with 60,616,648 shares represented, accounting for 30.6% of its outstanding shares. All proposals, including the election of directors and the appointment of KPMG LLP as auditors, received majority approval. Key director votes showed strong support, with Miguel Martin receiving 92.71% approval. Additionally, shareholders endorsed a non-binding advisory on executive compensation and renewed the shareholder rights plan. Complete voting results will be filed on SEDAR.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
none
Rhea-AI Summary

Aurora Cannabis reported its Q1 fiscal 2022 results, with total cannabis net revenue reaching $60.1 million, a 10% increase from the previous quarter. Medical cannabis revenue rose 23% year-over-year to $41.0 million. The company achieved $33 million in annualized cost savings, aiming for a total of $60 to $80 million. Adjusted EBITDA loss improved to $12.1 million, down from $19.7 million in Q4 2021. The adjusted gross margin before fair value adjustments improved to 54%. Aurora maintains a strong cash position of approximately $424.3 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
-
Rhea-AI Summary

Aurora Cannabis Inc. (NASDAQ: ACB) announced plans to invest in Growery B.V., a Dutch company involved in the Controlled Cannabis Supply Chain Experiment (CCSC). This investment marks a critical step in Aurora's strategy to enter the Netherlands' expected largest federally regulated recreational cannabis market outside Canada. The deal includes a secured loan for facility construction, with revenues consolidated under IFRS. Anticipated demand during the CCSC is around 30,000 kg annually, potentially rising to 200,000 kg if national expansion occurs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.61%
Tags
-
Rhea-AI Summary

Aurora Cannabis (ACB) announced a new manufacturing agreement with The Valens Company to produce seasonal cannabis products, starting with Canna Cane Mints, flavored peppermint candies infused with 10mg THC (5mg per piece). Set to launch under the Drift Turbo brand, these seasonal offerings aim to meet increasing consumer demand for variety. Additionally, a Cranberry Sauce vape cartridge will also be released in select Canadian markets. The partnership is expected to enhance product innovation while capitalizing on both companies' manufacturing strengths for the upcoming holiday season.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
Rhea-AI Summary

Aurora Cannabis Inc. (ACB) announced a conference call on November 9, 2021, at 5:00 p.m. ET to discuss its first-quarter fiscal results for 2022, which will be reported after market close the same day. This call will be hosted by CEO Miguel Martin and CFO Glen Ibbott. Investors can submit questions in advance. Aurora, a leader in the cannabis industry with a diverse product portfolio, continues to focus on growth and innovation in both medical and consumer markets. The company operates under the ticker symbol ACB on TSX and NASDAQ.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
conferences earnings
-
Rhea-AI Summary

High Tide Inc. has transitioned all Canna Cabana retail cannabis stores to a discount club model, enhancing its presence in the value segment and claiming the title of North America's largest cannabis discount retailer. The Cabana Club loyalty program offers exclusive low prices and benefits to over 245,000 members. This strategy aims to capture market share from the illicit cannabis sector, which accounts for 40% of sales, and reflects a successful pilot program that showed significant sales increases. High Tide plans to expand this model across Canada and potentially globally, leveraging its in-house brands.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
none
-
Rhea-AI Summary

High Tide has finalized its acquisition of an 80% stake in Blessed CBD for £9,064,000, enhancing its global e-commerce footprint. This marks High Tide's fifth e-commerce acquisition in 2021, increasing its e-commerce revenue run-rate from approximately $10.6 million to nearly $60 million. Blessed CBD, a leading CBD brand in the U.K. with significant site traffic, reported £5.1 million in revenue and £2.8 million in EBITDA for the year ending August 2021. The deal also includes options for High Tide to acquire the remaining 20% of Blessed CBD in three years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.66%
Tags
Rhea-AI Summary

High Tide Inc. has announced a definitive agreement to acquire 80% of Enigmaa Ltd., operating as Blessed CBD, for £9.06 million. Blessed is a leading UK CBD brand, known for its direct-to-consumer model with £5.1 million in revenue and strong gross margins of 81%. This acquisition aims to enhance High Tide's UK e-commerce presence and capitalize on cross-selling opportunities. The deal is expected to close in October 2021, with an option for High Tide to acquire the remaining 20% in three years, positioning the company for further growth in the EU CBD market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags

FAQ

What is the current stock price of Aurora Cannabis Common Shares (ACB)?

The current stock price of Aurora Cannabis Common Shares (ACB) is $4.23 as of November 18, 2024.

What is the market cap of Aurora Cannabis Common Shares (ACB)?

The market cap of Aurora Cannabis Common Shares (ACB) is approximately 233.5M.

What is Aurora Cannabis Inc. primarily known for?

Aurora Cannabis Inc. is known for the cultivation, production, and sale of high-quality cannabis products for both medical and recreational use.

Where is Aurora Cannabis Inc. headquartered?

Aurora Cannabis Inc. is headquartered in Edmonton, Alberta, Canada.

What are some of the brands under Aurora Cannabis?

Some of the brands under Aurora Cannabis include Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard.

What recent products has Aurora Cannabis launched?

Aurora Cannabis recently launched three new cannabis-infused beverages and resin cartridges in Australia, catering to patient needs with innovative and high-quality products.

What is Aurora's financial outlook for 2024?

Aurora expects to achieve positive free cash flow in calendar 2024 and has recently completed the repayment of nearly $465 million in convertible debt.

What significant acquisitions has Aurora made recently?

Aurora acquired the remaining equity interest in MedReleaf Australia, strengthening its position in the Australian medical cannabis market.

What certifications do Aurora's production facilities hold?

Aurora's production facilities hold EU-GMP and TGA-GMP certifications, ensuring compliance with rigorous international quality standards.

How does Aurora contribute to the U.S. cannabis market?

Aurora's wholly-owned subsidiary, Australis Capital Inc., actively participates in the U.S. cannabis market.

What international operations does Aurora have?

Aurora has expanded internationally through medical cannabis exporting agreements, with a significant presence in Europe and Australia.

How does Aurora ensure the quality of its products?

Aurora ensures the quality of its products through advanced cultivation techniques and compliance with international standards like EU-GMP and TGA-GMP.

Aurora Cannabis Inc. Common Shares

Nasdaq:ACB

ACB Rankings

ACB Stock Data

233.50M
54.75M
13.08%
5.13%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Edmonton